RegeneCure Starts Worldwide Veterinary Distribution of BoneCure Membrane Implant
Complete the form below to unlock access to ALL audio articles.
RegeneCure Ltd. has announced that the company has started to distribute its BoneCure® Membrane product to the veterinary market around the world.
The distribution follows the successful results of a recent clinical study in several EC countries and Israel. BoneCure Membrane was used by European Veterinary Surgeons in pets for the following indications: non-union, large bone gaps, arthrodesis and severe fractures.
The study showed that the healing time was about 40 percent quicker than normally observed using current Standard of Care therapies.
"Based on the outstanding safety and efficacy results of our clinical and pre-clinical studies, we expect BoneCure to enable veterinary surgeons to treat a larger number of severe fracture types and to significantly reduce the healing time and complication rate," said Moshe Tzabari, CEO of RegeneCure.
Distribution with dealers is now underway throughout Europe, Asia, Australia and the United States.
The use of the BoneCure Membrane for carpal arthrodesis is a major breakthrough in the surgery of companion animals that offers many advantages over the traditional “Gold Standard” procedure of harvesting an autogenous bone graft.
This procedure, described at the BoneCure website, prevents patient morbidity and pain, reduces the risks of infection and fracture at the donor site, saves operating time and eliminates the need for a second incision.
